Eli Lilly and Co (NYSE:LLY) has received mixed analyst ratings over the past three months, with a notable shift towards more bullish sentiments in recent evaluations. The average 12-month price target for LLY has been raised to $799.0, indicating a 12.89% increase from the previous target. Analysts from firms including Cantor Fitzgerald, Truist Securities, JP Morgan, and others have maintained or raised their ratings, with price targets ranging up to $1000.00. Eli Lilly's financial performance has been strong, with significant revenue growth, high net margin, and exceptional ROE and ROA, although its debt-to-equity ratio indicates a higher level of debt.